Aphton to Hold Conference Call to Discuss Latest Corporate Updates

Aphton Corporation (NASDAQ: APHT), a biotechnology
company focused on the development of immunotherapies for the
treatment of cancer, announced today that Patrick Mooney, M.D.,
Chairman and Chief Executive Officer, will hold a conference call to
discuss third quarter 2005 financials, the latest developments related
to the mutual agreement to dissolve the co-promotion and licensing
agreement with sanofi pasteur related to Aphton's anti-cancer product
Insegia(TM) (G17DT immunogen), and the Company's entry into a binding
letter of intent with the holders of the Company's Senior Convertible
Notes to exchange the outstanding principal balance under the notes
for cash and capital stock of the Company. The conference call will
take place at 9:00 a.m. ET on Thursday, November 10, 2005.
   A live audio webcast of the conference call can be accessed either
by telephone at:

   Toll Free in the US/Canada at 1-800-322-0079; Code Aphton
Corporation

   Outside the U.S. at 1-973-409-9258; Code Aphton Corporation

   Or via the internet at http://viavid.net/dce.aspx?sid=00002AC7.

   A replay of the presentation will be available via the website and
will begin approximately 2 hours after the conference call has
concluded and will be available for 14 days.

   About Aphton

   Aphton Corporation, headquartered in Philadelphia, Pennsylvania,
is a clinical stage biopharmaceutical company focused on developing
targeted immunotherapies for cancer. Aphton's products seek to empower
the body's own immune system to fight disease. Through the acquisition
of Igeneon AG in March 2005, Aphton acquired late-stage products,
IGN101, a cancer vaccine designed to induce an immune response against
EpCAM-positive tumor cells, and IGN311, a fully humanized antibody
against the Lewis Y antigen. Aphton has strategic alliances with Xoma
for treating gastrointestinal and other gastrin-sensitive cancers
using anti-gastrin monoclonal and other antibodies; and with Daiichi
Pure Chemicals for the development, manufacturing and
commercialization of gastrin-related diagnostic kits. Aphton's most
advanced product, Insegia(TM), targets the hormone gastrin 17 in an
attempt to treat gastrointestinal cancers. For more information about
Aphton or its programs please visit Aphton's website at
www.aphton.com.

   Safe Harbor

   This information is qualified in its entirety by cautionary
statements and risk factor disclosure contained in Aphton's Securities
and Exchange Commission filings, including Aphton's report on Form
10-K filed with the Commission on March 16, 2005. Aphton wishes to
caution readers that certain risks and uncertainties may have affected
and could in the future affect the drug development process and
Aphton's business and could cause actual results to differ materially
from Aphton's beliefs and expectations. These risk factors include,
but are not limited to: (1) Aphton's ability to consummate the
exchange of its convertible debt as contemplated by the binding letter
of intent; (2) Aphton's ability to fund the further development of its
research and development programs; (3) Aphton's ability to
successfully identify and consummate opportunities to broaden and
progress its research and development pipeline; (4) scientific
developments regarding immunotherapies; (5) Aphton's ability to
successfully integrate Igeneon's operations and product portfolio with
Aphton's operations and product portfolio; and (6) the actual design,
results and timing of preclinical and clinical studies for Aphton's
products and product candidates.